menu
    • menu
    [{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Carlyle","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"JK07","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Salubris Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"JK07","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Shenzhen Salubris Pharmaceuticals Co.Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Shenzhen Salubris Pharmaceuticals Co.Ltd."},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enarodustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Not Applicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"YolTech Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"YOLT-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD","highestDevelopmentStatusID":"14","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD"}]

    Find Clinical Drug Pipeline Developments & Deals by SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD

    Menu

    SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SHENZHEN SALUBRIS PHARMACEUTICALS

                            China arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            SHENZHEN SALUBRIS PHARMACEUTICALS

                            China arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YOLT-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : YolTech Therapeutics

                            Deal Size : $145.3 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            YolTech Signs Licensing Deal with Salubris For YOLT-101 in China

                            Details : YolTech will continue to advance the preclinical development of YOLT-101, while Salubris will be responsible for preparing and conducting clinical trials within the licensed territory.

                            Brand Name : YOLT-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 27, 2024

                            Lead Product(s) : YOLT-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : YolTech Therapeutics

                            Deal Size : $145.3 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SHENZHEN SALUBRIS PHARMACEUTICALS

                            China arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            SHENZHEN SALUBRIS PHARMACEUTICALS

                            China arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enarodustat

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Enarodustat (ONNARO®) Approved by NMPA for Treatment of Renal Anemia (Abstract) NMPA approved Enarodustat (ON...

                            Details : ONNARO (enarodustat) is a new generation of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was approved for the treatment of non-dialysis-dependent patients with anemia caused by chronic kidney disease.

                            Brand Name : Onnaro

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 09, 2023

                            Lead Product(s) : Enarodustat

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SHENZHEN SALUBRIS PHARMACEUTICALS

                            China arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            SHENZHEN SALUBRIS PHARMACEUTICALS

                            China arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Salubris Biotherapeutics

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeli...

                            Details : The financing will be used to advance and accelerate JK07, including the planned initiation of the first Phase 2 study in HFrEF and the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction.

                            Brand Name : JK07

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 28, 2023

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Salubris Biotherapeutics

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SHENZHEN SALUBRIS PHARMACEUTICALS

                            China arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            SHENZHEN SALUBRIS PHARMACEUTICALS

                            China arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Carlyle

                            Deal Size : $260.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China

                            Details : Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.

                            Brand Name : JK07

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 01, 2020

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Carlyle

                            Deal Size : $260.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth